440 related articles for article (PubMed ID: 32687266)
1. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
Cobb PW; Moon YW; Mezei K; Láng I; Bhat G; Chawla S; Hasal SJ; Schwartzberg LS
Cancer Med; 2020 Sep; 9(17):6234-6243. PubMed ID: 32687266
[TBL] [Abstract][Full Text] [Related]
2. Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.
Schwartzberg LS; Bhat G; Peguero J; Agajanian R; Bharadwaj JS; Restrepo A; Hlalah O; Mehmi I; Chawla S; Hasal SJ; Yang Z; Cobb PW
Oncologist; 2020 Aug; 25(8):e1233-e1241. PubMed ID: 32476162
[TBL] [Abstract][Full Text] [Related]
3. Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.
Barrett JA; Greene D; Lakshmikanthan S; Kolli P; Chawla S; Lebel F
J Clin Pharmacol; 2021 Feb; 61(2):204-210. PubMed ID: 32827162
[TBL] [Abstract][Full Text] [Related]
4. Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies.
Moon YW; Kim SK; Lee KS; Lee MH; Park YH; Park KH; Kim GM; Lim S; Lee SA; Choi JD; Baek E; Han H; Baek S; Im SA
Cancer Res Treat; 2023 Jul; 55(3):766-777. PubMed ID: 36701846
[TBL] [Abstract][Full Text] [Related]
5. An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.
Vacirca JL; Chan A; Mezei K; Adoo CS; Pápai Z; McGregor K; Okera M; Horváth Z; Landherr L; Hanslik J; Hager SJ; Ibrahim EN; Rostom M; Bhat G; Choi MR; Reddy G; Tedesco KL; Agajanian R; Láng I; Schwartzberg LS
Cancer Med; 2018 May; 7(5):1660-1669. PubMed ID: 29573207
[TBL] [Abstract][Full Text] [Related]
6. Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing.
Barrett JA; Choi J; Lakshmikanthan S; Kim YY; Greene D; Kolli P; Song TH; Choi IY; Kim YH; Lebel F
Exp Hematol; 2020 Dec; 92():51-61. PubMed ID: 33002567
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
[TBL] [Abstract][Full Text] [Related]
10. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
Lee KH; Kim JY; Lee MH; Han HS; Lim JH; Park KU; Park IH; Cho EK; Yoon SY; Kim JH; Choi IS; Park JH; Choi YJ; Kim HJ; Jung KH; Kim SY; Oh DY; Im SA
Support Care Cancer; 2016 Apr; 24(4):1709-17. PubMed ID: 26423618
[TBL] [Abstract][Full Text] [Related]
11. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
Bondarenko I; Gladkov OA; Elsaesser R; Buchner A; Bias P
BMC Cancer; 2013 Aug; 13():386. PubMed ID: 23945072
[TBL] [Abstract][Full Text] [Related]
13. An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
Zhang W; Jiang Z; Wang L; Li C; Xia J
Med Oncol; 2015 May; 32(5):147. PubMed ID: 25820754
[TBL] [Abstract][Full Text] [Related]
14. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
[TBL] [Abstract][Full Text] [Related]
15. Biosimilar pegfilgrastim and adherence to guidelines for chemotherapy-induced neutropenia and infections in cancer patients.
Danova M; Antonuzzo A; Spandonaro F; Pronzato P
Infez Med; 2020 Mar; 28(1):127-129. PubMed ID: 32172272
[TBL] [Abstract][Full Text] [Related]
16. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
Blackwell K; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Harbeck N
Ann Oncol; 2017 Sep; 28(9):2272-2277. PubMed ID: 28637287
[TBL] [Abstract][Full Text] [Related]
17. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Holmes FA; Jones SE; O'Shaughnessy J; Vukelja S; George T; Savin M; Richards D; Glaspy J; Meza L; Cohen G; Dhami M; Budman DR; Hackett J; Brassard M; Yang BB; Liang BC
Ann Oncol; 2002 Jun; 13(6):903-9. PubMed ID: 12123336
[TBL] [Abstract][Full Text] [Related]
18. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
von Minckwitz G; Kümmel S; du Bois A; Eiermann W; Eidtmann H; Gerber B; Hilfrich J; Huober J; Costa SD; Jackisch C; Grasshoff ST; Vescia S; Skacel T; Loibl S; Mehta KM; Kaufmann M;
Ann Oncol; 2008 Feb; 19(2):292-8. PubMed ID: 17846019
[TBL] [Abstract][Full Text] [Related]
19. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
[TBL] [Abstract][Full Text] [Related]
20. A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.
Leung M; Florendo J; Kano J; Marr-Del Monte T; Higgins B; Myers R; Menon T; Jones G
Support Care Cancer; 2015 Jun; 23(6):1669-77. PubMed ID: 25421443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]